Venlor: Restore Balance with Expert Depression & Anxiety Relief
| Product dosage: 75mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.95 | $56.76 (0%) | 🛒 Add to cart |
| 90 | $0.89 | $85.14 $79.98 (6%) | 🛒 Add to cart |
| 120 | $0.86 | $113.52 $103.20 (9%) | 🛒 Add to cart |
| 180 | $0.84 | $170.28 $150.50 (12%) | 🛒 Add to cart |
| 270 | $0.82 | $255.42 $221.02 (13%) | 🛒 Add to cart |
| 360 | $0.81
Best per pill | $340.56 $290.68 (15%) | 🛒 Add to cart |
Synonyms | |||
Venlor (venlafaxine hydrochloride) is a prescription serotonin-norepinephrine reuptake inhibitor (SNRI) developed for the management of major depressive disorder (MDD), generalized anxiety disorder (GAD), social anxiety disorder, and panic disorder. By modulating key neurotransmitters in the brain, it offers a dual mechanism of action that can provide robust symptom relief where selective serotonin reuptake inhibitors (SSRIs) may fall short. Under professional supervision, Venlor helps restore emotional stability, improve daily functioning, and support long-term mental wellness. It is available in immediate-release and extended-release formulations, allowing for tailored treatment approaches based on individual patient needs and response profiles.
Features
- Active ingredient: Venlafaxine hydrochloride
- Available formulations: Immediate-release tablets, extended-release capsules (Venlor XR)
- Standard strengths: 25 mg, 37.5 mg, 50 mg, 75 mg, 100 mg (tablets); 37.5 mg, 75 mg, 150 mg (capsules)
- Pharmacologic class: Serotonin-norepinephrine reuptake inhibitor (SNRI)
- Half-life: Approximately 5 hours (immediate-release), 11 hours (extended-release)
- Administration: Oral, with or without food
Benefits
- Dual reuptake inhibition targets both serotonin and norepinephrine, potentially offering broader efficacy
- Reduction in core depressive symptoms such as low mood, anhedonia, and fatigue
- Decreased anxiety, worry, and physical symptoms of anxiety disorders
- Improved social and occupational functioning over time
- Flexible dosing allows for individualized treatment regimens
- Extended-release formulation supports once-daily dosing and may improve compliance
Common use
Venlor is primarily indicated for the treatment of major depressive disorder (MDD) in adults. It is also approved for generalized anxiety disorder (GAD), social anxiety disorder (SAD), and panic disorder with or without agoraphobia. Off-label uses may include management of neuropathic pain, migraine prophylaxis, and treatment of vasomotor symptoms associated with menopause, though these should only be pursued under strict medical guidance. Diagnosis should be confirmed by a qualified healthcare provider based on DSM-5 or ICD-11 criteria before initiation.
Dosage and direction
Dosage must be individualized based on patient condition, tolerance, and treatment response. For major depressive disorder, the recommended starting dose for immediate-release Venlor is 75 mg/day, administered in two or three divided doses. This may be increased in increments of up to 75 mg/day at intervals of no less than 4 days, up to a maximum of 375 mg/day in severely depressed patients. For the extended-release formulation (Venlor XR), the starting dose is 75 mg once daily, which may be increased to 150 mg/day and further to a maximum of 225 mg/day if needed. For anxiety disorders, starting doses are typically lower—37.5 mg/day for immediate-release or 37.5 mg once daily for extended-release—with gradual titration based on tolerability and effect. Tablets should be swallowed whole with water; extended-release capsules must not be crushed, chewed, or placed in water. Consistent daily timing is advised to maintain steady plasma concentrations.
Precautions
Patients should be monitored closely for clinical worsening, suicidality, or unusual changes in behavior, especially during the initial months of therapy or after dose changes. Venlor may increase the risk of bleeding, particularly if used concomitantly with NSAIDs, aspirin, or anticoagulants. Caution is advised in patients with a history of seizures, bipolar disorder, or angle-closure glaucoma. Blood pressure should be monitored regularly due to the potential for dose-dependent hypertension. Abrupt discontinuation may lead to withdrawal symptoms; tapering is recommended. Use in pregnancy only if clearly needed; venlafaxine passes into breast milk. Not recommended during lactation unless potential benefits justify potential risks.
Contraindications
Venlor is contraindicated in patients with known hypersensitivity to venlafaxine or any excipient in the formulation. Concomitant use with monoamine oxidase inhibitors (MAOIs) is contraindicated due to risk of serotonin syndrome; a washout period of at least 14 days is required after discontinuing an MAOI before starting Venlor, and at least 7 days after stopping Venlor before starting an MAOI. Use is also contraindicated in patients with uncontrolled narrow-angle glaucoma.
Possible side effect
Common side effects may include nausea, headache, drowsiness, dry mouth, dizziness, insomnia, constipation, sweating, and nervousness. Sexual dysfunction (e.g., decreased libido, delayed ejaculation, anorgasmia) may occur. Less frequently, patients may experience increased blood pressure, palpitations, blurred vision, weight changes, or tremor. Serious side effects requiring immediate medical attention include signs of serotonin syndrome (agitation, hallucinations, fever, tachycardia, incoordination), severe skin reactions, abnormal bleeding, hyponatremia, or manic episodes. Most side effects are dose-dependent and may diminish over time.
Drug interaction
Venlor has significant interaction potential. Concomitant use with MAOIs is prohibited. Serotonergic drugs (e.g., other SSRIs, SNRIs, triptans, tramadol, tryptophan) may increase risk of serotonin syndrome. Drugs that inhibit CYP2D6 (e.g., quinidine, fluoxetine, paroxetine) may increase venlafaxine levels. Venlor may enhance the effects of warfarin and other anticoagulants. Caution is advised with drugs that affect blood pressure or heart rate. Avoid use with alcohol due to increased CNS depression.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next dose. In that case, skip the missed dose and resume the regular schedule. Do not double the dose to make up for a missed one. Patients should be advised to maintain a consistent dosing routine to avoid fluctuations in drug levels.
Overdose
Symptoms of overdose may include dizziness, sedation, tachycardia, changes in blood pressure, seizures, or serotonin syndrome. In case of suspected overdose, seek immediate medical attention or contact a poison control center. Treatment is supportive and symptomatic; there is no specific antidote. ECG monitoring is advised due to risk of QTc prolongation. Gastric lavage or activated charcoal may be considered if presented early.
Storage
Store at room temperature (15–30°C or 59–86°F) in a dry place, protected from light and moisture. Keep in the original container, tightly closed. Do not store in bathrooms or near sinks. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging.
Disclaimer
This information is intended for educational purposes only and does not replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting or changing any medication regimen. Do not disregard professional medical advice or delay seeking it based on information provided here. Individual patient responses may vary.
Reviews
Clinical studies and patient reports indicate that Venlor is effective in reducing symptoms of depression and anxiety for many individuals. Patients often note improved mood, reduced anxiety, and better daily functioning after several weeks of consistent use. Some report side effects such as initial nausea or sleep disturbances, which often subside. Adherence to prescribed dosing and open communication with a healthcare provider are frequently emphasized as key to successful treatment. Long-term users highlight the importance of not discontinuing abruptly. Always discuss personal experiences and adjustments with a prescribing physician.